Resear4ch Developments in Psoriasis
| Overview / Abstract: |
Plaque psoriasis is responsible for a substantial burden on patients, their families, and the healthcare system. To address this burden, important treatment advances continue to be made, including a better understanding of the long-term safety and efficacy of approved medications, as well as the introduction of new classes of medications. Join Steven Feldman, MD, PhD, and Abby Van Voorhees, MD, as they report on research results of these advances presented at the 2021 American Academy of Dermatology Virtual Meeting Experience. The faculty, and principal investigators of the research, also share their thoughts about the impact of the research findings on clinical practice. |
|
Expiration |
Jun 11, 2022 |
|
Discipline(s) |
Physician CME |
|
Format |
Webinar / Webcast / Video |
|
Credits / Hours |
1.25 AMA PRA Category 1 Credit(s)™. |
|
Accreditation |
ACCME |
|
Presenters / Authors / Faculty |
Steven Feldman, MD, PhD Abby Van Voorhees, MD |
|
Activity Specialities / Related Topics |
Dermatology, Pediatrics |
|
Sponsors / Supporters / Grant Providers |
This educational activity is supported by an educational grant from AbbVie, Janssen Biotech, Inc, administered by Janssen Scientific Affairs, LLC, and Novartis Pharmaceuticals Corp. |
|
Keywords / Search Terms |
Annenberg Center for Health Sciences at Eisenhower • soriasis Apremilast • Bimekizumab • Deucravacitinib • Guselkumab • Risankizumab • Secukinumab • Tildrakizumab • Ustekinumab • Biosimilars • Topical therapy Free CE CME |
|